NDC product
Doxorubicin Hydrochloride
NDC 68001-345 · BluePoint Laboratories
Key facts
| Product NDC | 68001-345 |
|---|---|
| Proprietary name | Doxorubicin Hydrochloride |
| Nonproprietary name | Doxorubicin Hydrochloride |
| Substances | DOXORUBICIN HYDROCHLORIDE |
| Dosage form | INJECTABLE, LIPOSOMAL |
| Route | INTRAVENOUS |
| Labeler | BluePoint Laboratories |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA208657 |
| Pharmacologic classes | Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA] |
| Marketing start | Feb 16, 2018 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: